Sodium channel protein type 1, 2, 3, 4, and 8 subunit alpha (Nav1.1/1.2/1.3/1.4/1.6)

The voltage-gated sodium channel (VGSC) group comprising isoforms Nav1.1, Nav1.2, Nav1.3, Nav1.4, and Nav1.6 represents the primary pore-forming alpha subunits responsible for the rapid influx of sodium ions that initiates and propagates action potentials in excitable tissues [1, 12]. These isoforms are predominantly expressed in the central nervous system (Nav1.1, 1.2, 1.3, 1.6) and skeletal muscle (Nav1.4), where they play distinct roles in neuronal firing thresholds, axonal conduction, and muscle contraction [4, 11, 18]. Mutations in the genes encoding these proteins (SCN1A, SCN2A, SCN3A, SCN4A, SCN8A) are associated with a wide spectrum of channelopathies, including severe epileptic encephalopathies, periodic paralysis, and chronic pain syndromes [6, 13]. Pharmacologically, this group is the target of many first-line anticonvulsants and local anesthetics, which typically act as non-selective blockers that stabilize the inactivated state of the channel to suppress pathological hyperexcitability [3, 5, 17]. While effective, the lack of isoform selectivity among traditional drugs like phenytoin and carbamazepine often leads to dose-limiting central nervous system side effects such as ataxia and dizziness [3, 15]. Furthermore, clinical management requires careful consideration of the specific isoform involved, as sodium channel blockers can paradoxically exacerbate seizures in patients with loss-of-function mutations in Nav1.1, such as those with Dravet syndrome [14].

Other names

SCN1ASCN2ASCN3ASCN4ASCN8AVoltage-gated sodium channel alpha subunitsVGSCTTX-sensitive sodium channels (excluding Nav1.7)

Use-dependent and voltage-dependent blockade of the sodium channel pore, primarily by binding to and stabilizing the inactivated state of the channel to reduce high-frequency firing.